Search

Displaying results 1461 - 1470 of 5263 in total
  1. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]

  2. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … When used in genetic therapy, this virus is modified for the elimination of its negligible integrative capacity by the removal of *rep* and *cap* and the insertion of the desired gene with its promoter

  3. Drug

    Polythiazide

    go.drugbank.com/drugs/DB01324
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)

  4. Drug

    Ceftaroline fosamil

    go.drugbank.com/drugs/DB06590
    ApprovedInvestigational

    Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections

    Synonyms: (6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  5. Drug

    Sincalide

    go.drugbank.com/drugs/DB09142
    Approved

    Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. … When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract.

  6. Drug

    Hydroxypropyl cellulose

    go.drugbank.com/drugs/DB00840
    Approved

    It is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis

  7. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.

  8. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH).

  9. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion

  10. Drug

    Carbazochrome

    go.drugbank.com/drugs/DB09012
    ApprovedWithdrawn

    It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries. … In the future this may prevent excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on effectiveness and severity of side effects remains inconclusive.

    International brands: Na Neng, Le Zhi Na